The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "The FDA's Guidance on Biosimilars: Understanding the Impact on Patent Prosecution and Litigation" on March 22, 2012 beginning at 2:00 pm (ET).  A panel consisting of Henry Hadad of Bristol-Myers Squibb Co., Erika Lietzan of Covington & Burling LLP, and Suzanne Munck of the Federal Trade Commission will discuss important clues in the new FDA guidance on how innovator companies should proceed in their patent prosecution to best evade biosimilar threats; hints for companies planning to enter the biosimilar market (sometimes a corporate entity that is also an innovator) on how to direct their patent and scientific strategy; and view from the chief counsel for IP at the Federal Trade Commission on patent litigation and the biosimilar marketplace.

The registration fee for the webinar is $120 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.